Evaluation of functional outcomes of Studer ileal orthotopic bladder substitutions

Abstract

Background: The most frequent cancer of the urinary system and the second leading cause of mortality from genitourinary cancers is urothelial carcinoma. The usual course of treatment for high-risk non-muscle invasive bladder cancer (NMIBC) and localized muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC). Methods: This one-armed hospital-based clinical trial study included 12 patients who were subjected to radical cystectomy and Studer ileal neo-bladder substitution at the urology department, Minia University, and Ain Shams University Hospital in the period from January 2022 to January 2023. Results: The mean age in our study was 63 years, with highest incidence in the age group (61:70 years), the mean blood loss and blood transfusion was 1166.5 ml, the mean operative time was 3.6 hours, total diurnal continence was achieved in 7 patients (58.5%) while 4 patients (33.5%) developed stress incontinence, and total nighttime continence was achieved in 5 patients (41.5%). Conclusion: Based on functional outcomes, we determined that Studer neobladder repair is safe in terms of effectiveness.